Research programme: ear disorder therapeutics - SALVAT
Latest Information Update: 28 Oct 2020
Price :
$50 *
At a glance
- Originator SALVAT
- Class Antibacterials; Antifungals
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ear disorders
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Ear disorders in Spain (Otic)
- 05 Oct 2018 Preclinical development for Ear disorders is ongoing in Spain (Salvat website, October 2018)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Ear disorders in Spain